Incidental Prophylactic Nodal Irradiation and Patterns of Nodal Relapse in Inoperable Early Stage NSCLC Patients Treated With SBRT: A Case-Matched Analysis

被引:28
|
作者
Lao, Louis [1 ,2 ]
Hope, Andrew J. [1 ]
Maganti, Manjula [3 ]
Brade, Anthony [1 ]
Bezjak, Andrea [1 ]
Saibishkumar, Elantholi P. [1 ]
Giuliani, Meredith [1 ]
Sun, Alexander [1 ]
Cho, B. C. John [1 ]
机构
[1] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada
[2] Auckland City Hosp, Dept Radiat Oncol, Auckland, New Zealand
[3] Univ Toronto, Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
关键词
CELL LUNG-CANCER; BODY RADIATION-THERAPY; DOSE-RESPONSE RELATIONSHIP; BEAM COMPUTED-TOMOGRAPHY; STEREOTACTIC RADIOTHERAPY; ELDERLY-PATIENTS; SURGERY; METASTASIS; RESECTION; FAILURE;
D O I
10.1016/j.ijrobp.2014.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Reported rates of non-small cell lung cancer (NSCLC) nodal failure following stereotactic body radiation therapy (SBRT) are lower than those reported in the surgical series when matched for stage. We hypothesized that this effect was due to incidental prophylactic nodal irradiation. Methods and Materials: A prospectively collected group of medically inoperable early stage NSCLC patients from 2004 to 2010 was used to identify cases with nodal relapses. Controls were matched to cases, 2: 1, controlling for tumor volume (ie, same or greater) and tumor location (ie, same lobe). Reference (normalized to equivalent dose for 2-Gy fractions [EQD2]) point doses at the ipsilateral hilum and carina, demographic data, and clinical outcomes were extracted from the medical records. Univariate conditional logistical regression analyses were performed with variables of interest. Results: Cases and controls were well matched except for size. The controls, as expected, had larger gross tumor volumes (P=.02). The mean ipsilateral hilar doses were 9.6 Gy and 22.4 Gy for cases and controls, respectively (P=.014). The mean carinal doses were 7.0 Gy and 9.2 Gy, respectively (P=.13). Mediastinal nodal relapses, with and without ipsilateral hilar relapse, were associated with mean ipsilateral hilar doses of 3.6 Gy and 19.8 Gy, respectively (P=.01). The conditional density plot appears to demonstrate an inverse dose-effect relationship between ipsilateral hilar normalized total dose and risk of ipsilateral hilar relapse. Conclusions: Incidental hilar dose greater than 20 Gy is significantly associated with fewer ipsilateral hilar relapses in inoperable early stage NSCLC patients treated with SBRT. (C) 2014 Elsevier Inc.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 25 条
  • [1] INCIDENTAL PROPHYLACTIC NODAL IRRADIATION AND PATTERNS OF NODAL RELAPSE IN INOPERABLE EARLY STAGE NSCLC PATIENTS TREATED WITH SBRT: A CASE-MATCHED ANALYSIS
    Lao, Louis
    Hope, Andrew
    Brade, Anthony
    Bezjak, Andrea
    Saibishkumar, Elantholi Parameswaran
    Giuliani, Meredith
    Sun, Alexander
    Cho, Byoung Chun J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S358 - S359
  • [2] Incidental Mediastinal Dose Does Not Explain Low Mediastinal Nodal Recurrence Rates in Early-Stage NSCLC Patients Treated With SBRT
    Rwigema, J.
    Wang, P.
    Lee, J.
    Garon, E.
    Lee, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S35 - S35
  • [3] Invasive Nodal Staging May Not Reduce Regional and Distant Recurrence Rates for Patients Treated with SBRT for Inoperable Stage I NSCLC
    Kennedy, W. R.
    Samson, P.
    Gabani, P.
    Nikitas, J.
    Robinson, C. G.
    Bradley, J. D.
    Roach, M. C., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E513 - E513
  • [4] A Radiomic Approach to Predict Nodal and Distant Relapse in Patients Treated with Stereotactic Body Radiation Therapy for Early Stage NSCLC
    Franceschini, D.
    Cozzi, L.
    Pezzulla, D.
    De Rose, F.
    Franzese, C.
    Tomatis, S.
    Scorsetti, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S891 - S892
  • [5] Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival A Propensity Score-matched NCDB Analysis
    Cantrell, James N.
    Acharya, Pawan
    Vesely, Sara K.
    Gunter, Tyler C.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (11): : 503 - 511
  • [6] Do Regional Nodal Pet SUVs Obtained At The Time Of Staging Predict For Treatment Outcomes In Patients Treated Receiving SBRT For Early-stage Medically Inoperable Lung Cancer?
    Haque, W.
    Videtic, G.
    Woody, N.
    Srinivas, S.
    Gupta, A.
    Reddy, C.
    Stephans, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S602 - S602
  • [7] The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy
    Vicini, FA
    Horwitz, EM
    Lacerna, MD
    Brown, DM
    White, J
    Dmuchowski, CF
    Kini, VR
    Martinez, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (05): : 1069 - 1076
  • [8] ANALYSIS OF INCIDENTAL RADIATION DOSE TO UNINVOLVED MEDIASTINAL/SUPRACLAVICULAR LYMPH NODES IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER TREATED WITHOUT ELECTIVE NODAL IRRADIATION
    Ahmed, Irfan
    DeMarco, Marylou
    Stevens, Craig W.
    Fulp, William J.
    Dilling, Thomas J.
    MEDICAL DOSIMETRY, 2011, 36 (04) : 440 - 447
  • [9] Integrating Radiomics and Circulating Tumor Cell Analysis Improves Prediction of Treatment Outcomes of Early Stage NSCLC Patients Treated with SBRT
    Jiao, Z.
    Li, H.
    Xiao, Y.
    Feigenberg, S. J.
    Kao, G. D.
    Fan, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S117 - S117
  • [10] Propensity-matched analysis of concurrent/sequential versus sequential immune checkpoint inhibition in inoperable stage III NSCLC patients treated with chemoradiotherapy.
    Kaesmann, Lukas
    Taugner, Julian
    Eze, Chukwuka
    Guggenberger, Julian
    Kenndoff, Saskia
    Floersch, Benedikt
    Tufman, Amanda
    Reinmuth, Niels
    Belka, Claus
    Manapov, Farkhad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)